Patent intelligence · US
US 11576983
Treatments for retinal disease
Treatments for retinal disease
Patent details — US 11576983
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 14, 2023
- Expiration
- Feb 9, 2043
- Applicant
- 4D MOLECULAR THERAPEUTICS INC.
- Claims
- 18
- CPC classes
- A61K, A61K48/0016, A61K48/0025, A61K48/0058
Quick answer
US 11576983 (Treatments for retinal disease) is held by 4D MOLECULAR THERAPEUTICS INC.. Status: granted. Granted Feb 14, 2023. Expires Feb 9, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- 4D MOLECULAR THERAPEUTICS INC.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K48/0016, A61K48/0025, A61K48/0058, A61K48/0075, A61K9/0019
More from 4D MOLECULAR THERAPEUTICS INC.
Related pharmaceutical patents in our USPTO index.
-
US 11840704
Adeno-associated virus variant capsids and methods of use thereof
granted -
US 11807868
Adeno-associated variants, formulations and methods for pulmonary delivery
granted -
US 11766489
Adeno-associated virus variant capsids and use for inhibiting angiogenesis
granted -
US 11766487
Treatments for retinal disease
granted -
US 11524081
Codon optimized REP1 genes and uses thereof
granted -
US 11499166
Adeno-associated variants, formulations and methods for pulmonary delivery
granted -
US 11419949
Adeno-associated virus variant capsids and methods of use thereof
granted
Frequently asked questions
What is US patent 11576983?
US 11576983 (Treatments for retinal disease) is held by 4D MOLECULAR THERAPEUTICS INC.. Status: granted. Granted Feb 14, 2023. Expires Feb 9, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11576983?
4D MOLECULAR THERAPEUTICS INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 15 pharmaceutical patents for this assignee.
When does US 11576983 expire?
Our index shows an expiration date of Feb 9, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.